Fact CheckerSign in

NCT06737367Completed

Integrating Machine Learning for Prognostic Prediction in Stage I NSCLC by CT Images and Pathological Factors

Integrating Machine Learning for Prognostic Prediction in Stage I NSCLC: a Multicenter Analysis

Source: ClinicalTrials.gov · Last updated 19 Dec 2024

Brief summary (registry, in English)

The investigators retrospectively collected the participants with stage I non-small cell lung cancer (NSCLC) patients resected between January 2010 to December 2020 for training and internal validation. The Clinical data, preoperative clinical information, laboratory results and CT images were collected. The investigators also collected the disease-free survival time. On the Deepwise multi-modal research platform, the images were semi-automatically segmented and expanded outward by 3mm to obtain the peritumor tissue. PyRadiomics was used to extract the radiomic features. LASSOcox and rsf were used to select the features. we developed a machine learning-based integrative prognostic model that utilizes radiomic and pathological variables as input using LOOCV framework. And it was further tested on the internal and external cohorts. Discrimination was assessed by using the C-index and area under the receiver operating characteristic curve (AUC), IBS, DCA.

Status (registry)
Completed
Study type
Observational
Enrollment
800 (actual)
First submitted
11 Dec 2024
Start date
Sept 2023
Primary completion date
Sept 2024
Lead sponsor
Jinling Hospital, China
Diseases
Lung cancer
NCT number
NCT06737367

What you commit to

  • Study type: Observational
  • Participants enrolled: 800
  • From Sept 2023 to the primary completion date, Sept 2024
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • death within 30 days of surgery

Other illness

  • history of lung cancer or synchronous lung cancers

Other

  • absence of enhanced CT
  • follow-up records ≤3 Months
  • carcinoma in situ (CIS) or minimally invasive NSCLC
  • no pathological slides or reports

Who the study is looking for

  • patients with stage I NSCLC (ninth AJCC edition) who underwent curative R0 resections between January 2010 and December 2020 -

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Jinling Hospital, China
Coordinator of this site? Confirm its status
NanjingChinaUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.